Literature DB >> 16700696

European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing.

G Kahlmeter1, D F J Brown, F W Goldstein, A P MacGowan, J W Mouton, I Odenholt, A Rodloff, C-J Soussy, M Steinbakk, F Soriano, O Stetsiouk.   

Abstract

The main objectives of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are to harmonise breakpoints for antimicrobial agents in Europe, and to act as the breakpoint committee for the European Medicines Agency (EMEA) during the registration of new antimicrobial agents. Detailed EUCAST procedures for harmonising and setting breakpoints for antimicrobial agents are available on the EUCAST website. Beginning with the current issue, a series of EUCAST Technical Notes will be published in CMI, based on the rationale documents produced by EUCAST for each of the antimicrobial agents studied, with the aim of highlighting important background information underlying decisions on breakpoints made by EUCAST.

Mesh:

Substances:

Year:  2006        PMID: 16700696     DOI: 10.1111/j.1469-0691.2006.01454.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  46 in total

1.  Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  M Cuenca-Estrella; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 2.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 3.  A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Authors:  A Dalhoff; P G Ambrose; J W Mouton
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

4.  Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results.

Authors:  Gunnar Kahlmeter; Christian G Giske; Thomas J Kirn; Susan E Sharp
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

5.  Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin.

Authors:  Delaney Burnard; Gemma Robertson; Andrew Henderson; Caitlin Falconer; Michelle J Bauer; Kyra Cottrell; Ian Gassiep; Robert Norton; David L Paterson; Patrick N A Harris
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

6.  Testing the optimality properties of a dual antibiotic treatment in a two-locus, two-allele model.

Authors:  Rafael Peña-Miller; Ayari Fuentes-Hernandez; Carlos Reding; Ivana Gudelj; Robert Beardmore
Journal:  J R Soc Interface       Date:  2014-05-08       Impact factor: 4.118

7.  An Aminoglycoside Antibacterial Substance, S-137-R, Produced by Newly Isolated Bacillus velezensis Strain RP137 from the Persian Gulf.

Authors:  Roya Pournejati; Ronald Gust; Hamid Reza Karbalaei-Heidari
Journal:  Curr Microbiol       Date:  2019-06-11       Impact factor: 2.188

8.  Interplay in the selection of fluoroquinolone resistance and bacterial fitness.

Authors:  Linda L Marcusson; Niels Frimodt-Møller; Diarmaid Hughes
Journal:  PLoS Pathog       Date:  2009-08-07       Impact factor: 6.823

9.  Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.

Authors:  Marie-Laure Joly-Guillou; Marie Kempf; Jean-Didier Cavallo; Monique Chomarat; Luc Dubreuil; Jeanne Maugein; Claudette Muller-Serieys; Micheline Roussel-Delvallez
Journal:  BMC Infect Dis       Date:  2010-03-18       Impact factor: 3.090

10.  MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.

Authors:  Kelly Stinson; Natalia Kurepina; Amour Venter; Mamoru Fujiwara; Masanori Kawasaki; Juliano Timm; Elena Shashkina; Barry N Kreiswirth; Yongge Liu; Makoto Matsumoto; Lawrence Geiter
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.